awmsg logo



levonorgestrel (Kyleena®)


Reference No. 3582

Publication date:
25/09/2018


Appraisal information

levonorgestrel (Kyleena®) 19.5 mg intrauterine delivery system


Company: Bayer plc
BNF category: Obstetrics, gynaecology, and urinary-tract disorders
NMG meeting date: 11/07/2018
AWMSG meeting date: 12/09/2018
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1318
Ratification by Welsh Government: 20/09/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Levonorgestrel (Kyleena®) is recommended as an option for use within NHS Wales for contraception for up to five years.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download